# Bleomycin

## BLEOCIN inj 15mg

##### 臨採

| TAH Drug Code      | [**IBLE1**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IBLE1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Carcinoma of the skin, head & neck, lung, oesophagus, uterine cervix & thyroid, malignant lymphomas, glioma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | 15-30 mg IV, IM or subQ twice weekly; 5-15 mg IA twice weekly.May adjust dosing frequency to once daily to once weekly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Severe pulmonary, renal or cardiac dysfunction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Severe interstitial pneumonia & pulmonary fibrosis, hypersensitivity, fever, haemorrhage, scleroderma-like changes in skin, anorexia, diarrhea, GI upsets; renal, urinary & neuropsychic disturbances, hypertrophy of venous wall, narrowing of venous lumen & induration around administration site. Phlebalgia with IV administration. Dermatologic: Alopecia (1-10%), Skin reaction - finding, Erythema, rash, striae, vesiculation, hyperpigmentation, skin tenderness (50%) Endocrine metabolic: Shivering Gastrointestinal: Nausea and vomiting, Stomatitis Psychiatric: Confusion Other: Fever |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

